載入中
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
前收盤價
US$7.83
−US$0.18 · -2.25%
盤中時間採用ET。市場資料可能有所延遲。
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
日內區間
目前US$7.83
52週區間
目前US$7.83
盤中時間採用ET。市場資料可能有所延遲。
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
日內區間
目前US$7.83
52週區間
目前US$7.83
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | 2227.05萬 USD | 2517.81萬 USD | 255.15萬 USD | 24.49萬 USD |
| 銷貨成本 | — | 4996.86萬 USD | 3644.8萬 USD | 2181.69萬 USD | — |
| 毛利 | — | −2769.81萬 USD | −1127萬 USD | −1926.55萬 USD | 24.49萬 USD |
| 研究與開發 | 8445.46萬 USD | 4996.86萬 USD | 3644.8萬 USD | 2181.69萬 USD | 1357.1萬 USD |
| 銷售、一般及管理費用 | 2274.86萬 USD | 1486.67萬 USD | 1280.79萬 USD | 1043.19萬 USD | 761.23萬 USD |
| 營業費用 | 1.08億 USD | 1486.67萬 USD | 1280.79萬 USD | 1043.19萬 USD | 2118.33萬 USD |
| 利息收入 | 625.76萬 USD | 220.3萬 USD | 172.87萬 USD | 52.15萬 USD | — |
| 利息支出 | 304.57萬 USD | — | — | — | — |
| 折舊和攤銷 | 188.9萬 USD | 142.52萬 USD | 106.89萬 USD | 53.31萬 USD | 24.57萬 USD |
| 營業利益 | −1.08億 USD | −4256.48萬 USD | −2407.79萬 USD | −2969.74萬 USD | −2093.84萬 USD |
| 淨利 | −1.05億 USD | −4046.72萬 USD | −2228.75萬 USD | −2901.95萬 USD | −2002.25萬 USD |
公司資料更新於 2026年10月11日。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2019年6月5日 | 1:10 | — | — |
股票分割 | 2013年11月21日 | 1:50 | — | — |
股票分割 | 2007年2月13日 | 1:10 | — | — |
已生效 2019年6月5日
1:10
已生效 2013年11月21日
1:50
已生效 2007年2月13日
1:10
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1640.47萬0.00%2.3兆 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI1444.69萬0.15%98.74億 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM1146.59萬0.01%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF590.67萬0.01%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO395.63萬0.03%139.17億 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO306.36萬0.02%180億 USD0.06%US$112.66+0.50%
Vanguard U.S. Momentum Factor ETFVFMO205萬0.10%19億 USD0.13%US$230.11+1.02%
Vanguard Health Care ETFVHT139.62萬0.01%220億 USD0.09%US$319.01+1.64%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOVanguard U.S. Momentum Factor ETFVFMOVanguard Health Care ETFVHTAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
